- Trials with a EudraCT protocol (330)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
330 result(s) found for: Endometrial.
Displaying page 2 of 17.
| EudraCT Number: 2020-005717-40 | Sponsor Protocol Number: 2001-FIVI-002-IC | Start Date*: 2021-05-05 |
| Sponsor Name:IVI Foundation | ||
| Full Title: Umbilical cord plasma for treating endometrial pathologies (thin endometrium / Ash erman’s syndrome/ endometria atrophy) | ||
| Medical condition: Endometrial pathologies (Thin endometrium/ Asherman's syndrome/ Endometrial atrophy) | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2016-001352-21 | Sponsor Protocol Number: ABT-C5-2016 | Start Date*: 2016-09-19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Ability Pharmaceuticals, SL | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A phase I/ II, open label study to assess the efficacy and safety of ABTL0812 in combination with paclitaxel and carboplatin in patients with advanced endometrial cancer or squamous NSCLC | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Squamous Cell Non-Small Cell Lung Cancer and advanced endometrial cancer | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2012-005546-38 | Sponsor Protocol Number: AEZS-108-050 | Start Date*: 2013-10-14 | ||||||||||||||||
| Sponsor Name:Aeterna Zentaris GmbH | ||||||||||||||||||
| Full Title: Randomised controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancer | ||||||||||||||||||
| Medical condition: Endometrial cancer, advanced, recurrent or metastatic | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: CZ (Completed) BE (Completed) GB (Completed) AT (Completed) DE (Completed) ES (Completed) IE (Completed) IT (Completed) BG (Completed) NL (Completed) PL (Completed) DK (Completed) FI (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2016-004617-28 | Sponsor Protocol Number: | Start Date*: 2017-11-30 | |||||||||||
| Sponsor Name:The University of Manchester | |||||||||||||
| Full Title: A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination with Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy as Second-Line Therapy for Advanced/Metastatic Endometria... | |||||||||||||
| Medical condition: Advanced or recurrent endometrial carcinoma or carcinosarcoma | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-000612-17 | Sponsor Protocol Number: HyperplasiLNG | Start Date*: Information not available in EudraCT |
| Sponsor Name:University Hospital of North Norway | ||
| Full Title: Significance of intrauterine progestogen therapy in endometrial proliferative conditions | ||
| Medical condition: Endometrial cancer has presently become the most frequent gynaecologic malinancy in the Western World and the incidence is still increasing. In Norway a 50% increase in occurence has been observed ... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: NO (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2017-000607-25 | Sponsor Protocol Number: KCP-330-024BGOG-EN5/ENGOT-EN5/SIEND | Start Date*: 2017-11-22 | |||||||||||||||||||||
| Sponsor Name:Karyopharm Therapeutics Inc. | |||||||||||||||||||||||
| Full Title: A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer | |||||||||||||||||||||||
| Medical condition: Selinexor/placebo will be given as maintenance therapy after combination chemotherapy for patients with advanced endometrial cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||||||||||||
| Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) PL (Completed) IT (Trial now transitioned) GR (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2010-023457-11 | Sponsor Protocol Number: S52798 | Start Date*: 2011-02-15 | ||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:UZ Leuven | ||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Immune regulation and timing of chemotherapy in advanced/recurrent ovarian and endometrial cancer | ||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: advanced/recurrent ovarian and endometrial cancer | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2014-002352-12 | Sponsor Protocol Number: OTL-038 | Start Date*: 2014-08-18 | |||||||||||||||||||||
| Sponsor Name:On Target Laboratories , LLC | |||||||||||||||||||||||
| Full Title: A Single Ascending Dose, Open Label, Exploratory Study of OTL-038 for the Intra-operative Imaging of Folate Receptor Alpha Positive Ovarian, Renal Cell and Endometrial Cancer | |||||||||||||||||||||||
| Medical condition: Primary ovarian cancer planned for either primary debulking surgery or interval debulking surgery by laparotomy or planned for surgical staging by laparoscopy. Primary renal cell carcinoma planned... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2021-004061-13 | Sponsor Protocol Number: ESR21-21165 | Start Date*: 2022-06-09 | ||||||||||||||||
| Sponsor Name:VHIO Vall d’Hebron Institute of Oncology | ||||||||||||||||||
| Full Title: Single cell characterization of persistent cells upon treatment with durvalumab (MEDI4736) with or without tremelimumab in MSS and MSI colorectal and endometrial tumors | ||||||||||||||||||
| Medical condition: MSS and MSI colorectal and endometrial tumors | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2021-002124-21 | Sponsor Protocol Number: GINECO-EN105b | Start Date*: 2021-12-21 | |||||||||||
| Sponsor Name:ARCAGY-GINECO | |||||||||||||
| Full Title: Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanced/metastatic setting: DOMENICA STUDY (GINECO-EN105b/ENGO... | |||||||||||||
| Medical condition: Endometrial cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-000496-20 | Sponsor Protocol Number: INCMGA0012-204 | Start Date*: 2021-01-08 | ||||||||||||||||
| Sponsor Name:Incyte Corporation | ||||||||||||||||||
| Full Title: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemothe... | ||||||||||||||||||
| Medical condition: Endometrial cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: FR (Trial now transitioned) DE (Prematurely Ended) BE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2007-004917-33 | Sponsor Protocol Number: LUMCP06.031 | Start Date*: 2008-12-16 | |||||||||||||||||||||
| Sponsor Name:Leiden University Medical Centre | |||||||||||||||||||||||
| Full Title: A Randomised Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma | |||||||||||||||||||||||
| Medical condition: Endometrial carcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) AT (Ongoing) FR (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2022-002540-42 | Sponsor Protocol Number: XPORT-EC-042 | Start Date*: 2023-03-15 | |||||||||||||||||||||
| Sponsor Name:Karyopharm Therapeutics Inc. | |||||||||||||||||||||||
| Full Title: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETR... | |||||||||||||||||||||||
| Medical condition: Selinexor/placebo will be given as maintenance therapy after combination chemotherapy for patients with p53 wild-type, advanced or recurrent endometrial cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||||||||||||
| Trial protocol: ES (Ongoing) DE (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) IE (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2016-001716-38 | Sponsor Protocol Number: 1404-BIO-019-MF | Start Date*: 2017-04-26 |
| Sponsor Name:IVI BILBAO | ||
| Full Title: Influence instillation plasma rich in growth factors in endometrial cavity | ||
| Medical condition: Women receiving cycle of oocytes outside or embryos (own / others), in the treatment of substituted cycle type. Less than 5 mm Endometrio despite 10 days with standard doses of estrogen therapy (6... | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: ES (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2010-024396-12 | Sponsor Protocol Number: CBEZ235C2201 | Start Date*: 2011-06-13 | |||||||||||
| Sponsor Name:Novartis Pharma Services AG | |||||||||||||
| Full Title: A Phase II, single-arm study of orally administered BEZ235 as second-line therapy in patients with advanced endometrial carcinoma | |||||||||||||
| Medical condition: Patients who have experienced progression of disease after first-line antineoplasic treatment of advanced endometrial carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: CZ (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-000266-35 | Sponsor Protocol Number: CTKI258A2211 | Start Date*: 2012-03-21 | |||||||||||
| Sponsor Name:NOVARTIS FARMA | |||||||||||||
| Full Title: A phase II, open-label, single-arm, non-randomized, multi-center study to evaluate the efficacy of oral TKI258 as second-line therapy in patients with either FGFR2 mutated or wild-type advanced and... | |||||||||||||
| Medical condition: Advanced and/or metastatic endometrial carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) ES (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-003009-24 | Sponsor Protocol Number: MK-7902-001 | Start Date*: 2020-03-18 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. | |||||||||||||
| Full Title: A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-... | |||||||||||||
| Medical condition: Advanced Endometrial Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: AT (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-004387-35 | Sponsor Protocol Number: MK-3475-775/E7080-G000-309 | Start Date*: 2018-06-13 | |||||||||||
| Sponsor Name:Eisai Ltd | |||||||||||||
| Full Title: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with A... | |||||||||||||
| Medical condition: Advanced Endometrial Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: FR (Completed) ES (Ongoing) IE (Completed) GB (GB - no longer in EU/EEA) PL (Completed) IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-000290-12 | Sponsor Protocol Number: 1412-BCN-087-AB | Start Date*: 2015-06-26 |
| Sponsor Name:Clínica IVI Barcelona | ||
| Full Title: Randomized Clinical Trial comparing the endometrial transformation with 25 mg/day of subcutaneous progesterone (Prolutex) versus 50 mg/day intramuscular progesterone (Prontogest) | ||
| Medical condition: Infertility. Assisted Reproductive Techniques. | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: ES (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-000070-19 | Sponsor Protocol Number: CRUKD/14/001 | Start Date*: 2015-06-19 | ||||||||||||||||||||||||||
| Sponsor Name:Cancer Research UK | ||||||||||||||||||||||||||||
| Full Title: A Cancer Research UK Phase I Study of MOv18 IgE, a first in class chimeric IgE antibody against folate receptor-α, in patients with advanced solid tumours | ||||||||||||||||||||||||||||
| Medical condition: Advanced unresectable solid tumour of a type known to express folate receptor alpha (FRα) in a percentage of cases for which no alternative therapy is felt to be appropriate. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
